Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Review symbols : Azn save search
Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Published: 2024-03-01 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -0.43%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.59%
H: 2.06%
C: 2.06%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.28%
H: 0.75%
C: 0.4%
review cancer trials global trial
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.24%
H: 0.07%
C: -0.1%
enhertu her2 granted review tumors positive
S&P Dow Jones Indices Announces Dow Jones Sustainability Indices 2023 Review Results
Published: 2023-12-08 (Crawled : 23:00) - prnewswire.com
TCEHY | News | $38.94 0.04% 3.8M
|
Information
| Email alert
Add to watchlist
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
TCTZF | News | $38.63 2.11% 6.6K
|
Technology Services
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
SPGI | News | $412.56 -0.2% 0.0% 1.1M
|
Commercial Services
| Email alert
Add to watchlist
DNOW | $14.65 -0.54% 0.0% 670K
|
Distribution Services
| Email alert
Add to watchlist
jones review results
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.155 -8.28% -9.03% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 2.56%
C: 2.56%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.63%
H: 4.97%
C: 2.76%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 0.47%
H: 1.7%
C: -0.38%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
fda year review cancer pancreatic
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.34%
H: 0.21%
C: -2.03%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.12%
H: 2.16%
C: -10.76%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.44%
H: 0.03%
C: -1.94%
reqorsa lung approval review cancer cell expansion trial
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.61%
H: 1.82%
C: 1.82%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 2.34%
H: 5.98%
C: -0.85%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.76%
H: 1.04%
C: 0.47%
reqorsa lung trial approval review cancer
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Published: 2022-08-15 (Crawled : 12:20) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -0.09%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 7.91%
H: 13.09%
C: 9.42%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
tagrisso lung trial review cancer phase 1
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Published: 2022-07-25 (Crawled : 12:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
Published: 2022-07-25 (Crawled : 11:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
Published: 2022-04-25 (Crawled : 13:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.72%
H: 1.65%
C: 1.52%
liver review cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2022-04-19 (Crawled : 11:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.44%
H: 0.66%
C: -0.42%
enhertu granted review cancer her2- her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.